Navigation Links
New Hope to Beat Cancer
Date:3/12/2009

Aurora St. Luke's is one of a few institutions in the world to offer skin cancer clinical trial.

MILWAUKEE, March 12 /PRNewswire/ -- Aurora St. Luke's Medical Center is one of the first institutions in the world to offer a new skin cancer research study that trains the patient's immune system to kill cancer cells.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b)

The Young Tumor-Infiltrating Lymphocyte (Y-TIL) trial is a phase 2 clinical trial being offered with technical support from the National Cancer Institute (NCI) in Bethesda, Md. Milwaukee native Jeff Capstran participated in an earlier stage of this trial at NCI. Capstran had stage-four metastatic melanoma, a diagnosis that few survive, but with small kids at home he was determined to find treatment options.

"I knew that my illness was very serious, but there had to be new opportunities to fight back," Capstran says. "When I found out about the study at NCI, I knew I had to jump at the chance. Today, I am cancer free."

The early results from a similar trial at the NCI are exciting for patients with stage-four metastatic melanoma. Published reports for the trial show a 51 percent response rate.

To qualify, all patients must be diagnosed with stage-four metastatic melanoma. During the trial blood is drawn from the patient, along with a sample of the tumor. The T cells, which are the immune system's killer cells, are extracted from the tumor and re-educated to attack the cancer cells. The patient's normal immune system is then temporarily suppressed using chemotherapy, and the newly trained T cells are returned to the patient. The T cells are expected to survive, replicate and kill the cancer.

The trial has a capacity for 75 patients over a three-year period. Of those 41 are expected to qualify for the entire process. With the success of this program, the next step is a phase 3 trial where hundreds of patients would be enrolled and treated.

Due to the experimental features of this clinical trial, some portions of the study may not be covered by health insurance. As a not-for-profit, Aurora Health Care's philanthropy program has secured more than $2 million in support from outside donors, including $50,000 from Anne's Hope Foundation.

Milwaukee's own Northwestern Mutual Foundation has made its largest health care donation of $750,000 to Aurora's immunotherapy program, which has oversight of the Y-TIL Trial. Other contributors include A. Elser, Jr., William Schuett, Sr., Stella Jones and Sherwood and Libby Temkin.

To keep the trial affordable for all who participate, an additional $700,000 in donations is being sought for each year of the program, a total of over $2,000,000.

Aurora Health Care is a not-for-profit Wisconsin health care provider and a national leader in efforts to improve the quality of care. Aurora provides care at sites in more than 90 communities throughout eastern Wisconsin and Illinois.

Online newsroom: www.Aurora.org/Newsroom

Clinical trial information: www.aurora.org/y-til


'/>"/>
SOURCE Aurora Health Care
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2017. The cash ... about October 27, 2017 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)... , Aug. 2, 2017 CaryRx, a next-generation full-service ... delivery service for patients in the Washington D.C. ... retail pharmacy by providing delivery of medications through the convenience ... future delivery or delivered within one hour to any location ... excited to bring this invaluable service to Washington ...
Breaking Medicine Technology:
(Date:8/18/2017)... CA & CARMEL, IN (PRWEB) , ... August 18, 2017 , ... ... on its 36th annual list, the most prestigious ranking of the nation's fastest-growing private ... been included in the exclusive Inc. 5000 ranking . This year’s ranking reflects ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Three Narrow Roads”: a vivid and ... of published author, Rev. Dr. Burnett King Sr., is currently the pastor-teacher-visionary at Simply ... the Faith Track Club, Inc., a track-and-field program geared towards youth. , King shares, ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Kingdom Mandate for Kingdom Builders”: ... “Kingdom Mandate for Kingdom Builders” is the creation of published author, John F. ... Eastern Europe as a missionary in 1983. He spent three decades training pastors ...
(Date:8/17/2017)... ... August 17, 2017 , ... Riccobene Associates ... location in Goldsboro, NC to its family of practices. Residents of Goldsboro will ... starting August 15, 2017. , Riccobene Associates Family Dentistry, founded by Dr. ...
(Date:8/17/2017)... MA (PRWEB) , ... August 17, 2017 , ... ... will come together on September 19, 2017 for Anti-Infectives Rx. This off-the-record networking ... B. Martin Conference Center at Harvard Medical School. , Industry leaders and decision ...
Breaking Medicine News(10 mins):